tucidinostat + pembrolizumab

Tucidinostat + pembrolizumab is a combination of an oral, selective histone deacetylase (HDAC) inhibitor (tucidinostat, also called chidamide) with a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor (pembrolizumab). Tucidinostat inhibits HDAC1, HDAC2, HDAC3, and HDAC10, leading to epigenetic modulation with direct antitumor and immunomodulatory effects, which include enhancing CD8+ T cell recruitment, promoting anti-tumor immune microenvironment remodeling, and potentiating immune checkpoint blockade[1][2][3]. Pembrolizumab is a monoclonal antibody that binds to and inhibits the PD-1 receptor, blocking its interaction with PD-L1/PD-L2, thereby restoring T cell activity against cancer cells[4]. Preclinical and early clinical data show that combining tucidinostat with immune checkpoint inhibitors, including pembrolizumab, can synergistically enhance anti-tumor efficacy by amplifying anti-cancer immune responses and overcoming tumor immune evasion[1][2][3]. This combination is being investigated clinically for solid tumors and hematological malignancies, though the majority of published clinical studies use other anti-PD-1 antibodies (such as sintilimab or toripalimab) in combination with tucidinostat, with pembrolizumab suggested by mechanism and as a class representative[1][3].

Brand names

Epidaza + KeytrudaHiyasta + Keytruda

Other names

chidamide + pembrolizumab